Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer

Table 1

Baseline characteristics of 65 locally advanced/metastatic gastric cancer patients.

		N = 65 (%)
Age, years
Mean (range)		65.4 (31–85)
≧65 years		33 (50.8)
<65 years		32 (49.2)
Gender
Male		42 (64.6)
Female		23 (35.4)
Tumor size
<5 cm		36 (55.4)
≧5 cm		29 (44.6)
Clinical T status
T4		47 (72.3)
T3		18 (27.7)
Clinical N status
N1		10 (15.4)
N2 + N3		55 (84.6)
Vascular invasion
Positive		10 (15.4)
Negative		13 (20.0)
ND		42 (64.6)
Perineural invasion
Positive		11 (16.9)
Negative		12 (18.5)
ND		42 (64.6)
Clinical TNM stage
Stage III		41 (63.1)
Stage IV		24 (36.9)
Tumor location
Cardiac		18 (27.7)
Body		18 (27.7)
Antrum		31 (47.7)
Diffuse (borrmann IV)		18 (27.7)
Stump		3 (4.6)
Histology
Well-differentiated	0
Moderately differentiated		15 (23.1)
Poorly differentiated		50 (76.9)
Metastasis site
Peritoneum carcinomatosis		8 (12.3)
Liver		7 (10.8)
Lung		6 (9.2)
Bone		2 (3.1)
Ovary		3 (4.6)
Bladder		1 (1.5)
Pretreatment CEA (ng/ml)
≧5		16 (24.6)
<5		49 (75.4)
Posttreatment CEA (ng/ml)
≧5		20 (30.8)
<5		45 (69.2)
TNM downstaging
Yes		18 (27.7)
No		47 (72.3)
T downstaging
Yes		17 (26.2)
No		48 (73.8)
N downstaging
Yes		16 (24.6)
No		49 (75.4)
R0/R1 resection
Yes		25 (38.5)
No		40 (61.5)
CCRT or chemotherapy
CCRT		30 (46.2)
Chemotherapy		35 (53.8)

ND=Not done (38 patients: unresectable tumor; 2 patients: complete response after neoadjuvant chemoradiotherapy); CEA: carcinoembryonic antigen; CCRT = concurrent chemoradiotherapy.